Cognition Therapeutics Inc (NAS:CGTX)
$ 2.55 -0.05 (-1.92%) Market Cap: 102.15 Mil Enterprise Value: 68.51 Mil PE Ratio: 0 PB Ratio: 3.53 GF Score: 22/100

Cognition Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 11, 2022 / 07:00PM GMT
Release Date Price: $3.18 (+1.60%)
Ami Fadia
Needham & Company, LLC - Analyst

Good afternoon, everyone. Welcome again to the next session with Cognition Therapeutics. I'm Ami Fadia; I cover neuroscience and targeted oncology here at Needham. And it's my pleasure to be hosting Lisa Ricciardi, who's the CEO of the company; as well as Jim O'Brien, who is the Chief Financial Officer. Lisa will be taking you through a presentation. (Conference Instructions)

With that, Lisa, please go ahead.

Lisa Ricciardi
Cognition Therapeutics, Inc. - CEO

Thank you, Ami. A pleasure to be here. Thank you for including us at Needham's panel this afternoon. I was so eager to get to the forward-looking statement, now I'm struggling to get back to it. So here you have it. We completed our IPO in October and are delighted to have raised the money we need for our trials.

Brief background on our company. Neurodegenerative disorders, age-related neurodegenerative disorders, and specifically, the central nervous system as well as the retina, which in shorthand means Alzheimer's disease, dementia with

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot